Literatur

Akassoglou, K., Bauer, J., Kassiotis, G., Pasparakis, M., Lassmann, H., Kollias, G, Probert, L. 1998: Oligodendrocyte Apoptosis and Primary Demyelination Induced by Local TNF/p55TNF Receptor Signaling in the Central Nervous System of Transgenic Mice. American Journal of Pathology, 153; 801-813.

Andersson, M., Alvarez-Cermeno, J., Bernardi, G., Cogato, I., Fredman, P., Frederiksen, J., Fredrikson, S., Gallo, P., Grimaldi, L.M., Gronning, M. et al. 1994: Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report. Journal of Neurology, Neurosurgery and Psychiatry , 57; 897-902.

Bates, S., Vousden, K.H. 1999: Mechanisms of p53 mediated apoptosis. Cellular and Molecular Life Sciences, 55; 28-37.

Bauer, J., Stadelmann, C., Bancher, C. Jellinger, K., Lassmann, H. 1999 : Apoptosis of T Lymphocytes in acute disseminated encephalomyelitis . Acta Neuropathologica, 97; 543-546.

Berger, T., Weerth, S. Kojima, K., Linington, C., Wekerle, H., Lassmann, H. 1997: Experimental autoimmune encephalomyelitis: The antigen specifity of T-Lymphocytes determines the topography of lesions in the central and peripheral nervous system. Laboratory Investigations, 76; 355-364.

Bonetti, B., Raine, C.S. 1994: Multiple Sclerosis: oligodendrocytes display cell death-related molecules but do not undergo apoptosis. Annals of Neurology, 42; 74-84.

Bronnum-Hansen, H., Koch-Henriksen, N., Hyllested, K. 1994: Survival of Patients with multiple sclerosis in Denmark: A nationwide, long term epidemiologic survey . Neurology, 44; 1901-1907.

Brück, W., Porada, P., Poser, S., Rieckmann, P., Hanefeld, F., Kretzschmar, H.A., Lassmann, H. 1995: Monocyte/Macrophage differentiation in early multiple sclerosis lesions. Annuals of Neurology , 38; 554-566.

[Seite 49↓]

Brück, W., Schmied, M., Suchanek, G., Brück, Y, Breitschopf, H., Poser, S., Piddlesden, S., Lassmann, H. 1994 : Oligodendrocytes in the Early Course of Multiple Sclerosis. Annals of Neurology , 35; 65-73.

Burgmaier, G., Schönrock, M.L., Kuhlmann, T., Richter-Landsberg, C., Brück, W. 2000: Association of increased bcl-2 expression with rescue from TNF- α induced cell death in the oligodendrocyte cell line OLN-93. Journal of Neurochemistry, 75; 2270-2276.

Cammer, W. 2000: Effects of TNF- α on immature and mature oligodendrocytes and their progenitors in vitro . Brain research, 864; 213-219.

Carbone, D., Chiba, I., Mitsudomi, T. 1991: Polymorphism at codon 213 within the p53 gene. Oncogene, 6 1691-1692.

Casaccia-Bonnefil, P. 2000 : Cell Death in the Oligodendrocyte Lineage: A molecular Perspective of Life/Death Decisions in Development and Disease. Glia , 29; 124-135.

Caulin, C., Salvesen, G.S., Oshima, R.G. 1997 : Caspase cleavage of keratin 18 and reorganization of intermediate filaments during epithelial cell apoptosis. Journal of Cell Biology, 138; 1379-1394.

Celius, E.G., Harbo, H.F., Egeland, T., Vartdal, F., Vandvik, B., Spurkiand, A. 2000: Sex and age at diagnosis are correlated with the HLA-DR2, DQ6 haplotype in multiple sclerosis. Journal of Neurological Sciences, 178; 132-135.

Charcot, J.M. 1868 : Histologie de la sclérose en plaques . Gaz Hôp, 41; 554-555, 557-558, 566.

Chataway, J., Feakes, R., Coraddu, F., Gray, J., Deans, J., Fraser, M., Robertson, N., Broadley, S., Jones, H., Clayton, D., Goodfellow, P., Sawcer, S. Compston, A. 1998: The genetics of multiple sclerosis: principles, background and updated results of The United Kingdom systematic genome screen. Brain , 121; 1869-1887.

[Seite 50↓]

Chehab, N.H., Malikazay, A., Appel, M., Halazonetis, T.D. 2000: Chk2/hCds1 functions as a DNA damage checkpoint in G1 by stabilizing p53. Genes & Development, 14; 278-288.

Cho, Y., Gorina, S., Jeffrey, J.D., Pavletich, N.P. 1994: Crystal structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations. Science, 265; 346-355.

Chung, H.T., Pae, H.O., Choi, B.M., Billiar, T.R., Kim, Y.M. 2001 : Nitric Oxide as a Bioregulator of Apoptosis. Biochemical and Biophysical Research Communications, 282; 1075-1079.

Comi, G., Fillipi, M., Wolinsky, J.S. 2001 : European/Canadian multicenter, double-blind, randomized, placebocontrolled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing remitting multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Annals of Neurology, 49; 290-297.

Compston, D.A.S. 1990: The Dissemination of multiple sclerosis. The Langdon-Brown lecture 1989. Journal of the Royal College of Physicians London, 24; 207-218.

Compston, A.: Genetic susceptibility to multiple sclerosis. In: Mc Alpine´s Multiple Sclerosis (ed. A.Compston) 3rd edition , London: Churchill Livingstone, 1998 . pp. 101-142

Coraddu, F., Sawcer, S., Feakes, R., Chataway, J., Broadley, S., Jones, H.B., Clayton, D., Gray, J., Smith, S. Taylor, C., Goodfellow, P.N., Compston, A. 1998: HLA typing in the multiple sclerosis genome screen . Neurogenetics , 2 ; 24-33.

Correale, M.D., Gilmore, W., Li, S., Walsh, J., Bassani, M.M., Lund, B., Arias, M., Weiner, L.P. 2000 : Resistance to glucocorticoid-induced apoptosis in PLP peptide-specific T cell clones from patients with chronic MS . Journal of Neuroimmunology, 109; 197-210.

[Seite 51↓]

Cowan, J.M.A., Dick, J.P.R., Day, B.L., Rothwell, J.C., Thompson, P.D., Marsden, C.D. 1984: Abnonormalities in central motor pathway conduction in multiple sclerosis. Lancet, 2; 304-307.

Dean, G. 1967: Annual incidence, prevalence, and mortality of multiple sclerosis in white South-African-born and in white immigrants to South Africa. British Medical Journal, 2; 724-730.

Detels, R., Visscher, B.R., Malmgren, R.M., Coulson, A.H., Lucia, M.V., Dudley, J.P. 1977: Evidence for lower susceptibility to multiple sclerosis in Japanese-Americans. American Journal of Epidemiology, 105; 303-310.

Dowling, P., Ming, X., Raval, S, Husar, W., Cassacia-Bonnefil, P. Chao, M. Cook, S., Blumberg, B. 1999: Upregulated p75NTR neurotrophin receptor on glial cells in MS plaques. Neurology , 53; 1615-1616.

D´Souza, S.D., Bonetti, B., Balasingam, V., Cashman, N.R., Barker, P.A., Troutt, A.B., Raine, C.S., Antel, J.P. 1996: Multiple Sclerosis: Fas Signaling in Oligodendrocyte Cell Death. Journal of Experimental Medicine, 184; 2361-2370.

D´Souza, S.d., Alinauskas, K.A., Antel, J.P . 1996: Ciliary Neurotrophic Factor Selectively Protects Human Oligodendrocytes From Tumor Necrosis Fator-Mediated Injury. Journal of Neuroscience Research, 43; 289-298.

Ebers G.C., Sadovnick A.D. 1994 : Association studies in multiple sclerosis. Journal of Neuroepidemiology, 53; 117-122.

Eizenberg, O., Faber-Elman, A., Gottlieb, E., Oren, M., Rotter, V. Schwartz, M. 1996: p53 plays a Regulatory Role in Differentiation and Apoptosis of Central Nervous System-Associated Cells. Molecular and Cellular Biology, 16; 5178-5185.

Fesus, L. 1993: Biochemical events in naturally occurring forms of cell death. FEBS Letters , 328;1-5.

[Seite 52↓]

Fraser, A., Evan, G. 1996: A License to kill. Cell, 85; 781-784.

Garell, P.C., Menezes, A.H., Baumbach, G., Moore, S.A., Nelson, G., Mathews, A.K. 1998: Presentation, Management and follow-up of Schilder´s disease. Pediatric Neurosurgery, 29; 86-91.

Gold, R., Hartung, H-P, Lassmann, H. 1997: T-cell apoptosis in autoimmune diseases: termination of inflammation in the nervous system and other sites with specialized immune-defense mechanisms. Trends in Neurosciences, 20; 399-404.

Gostissa, M., Henstermann, A., Fogal, V., Sandy, P., Schwarz, S.E., Scheffner, M., Del Sal, G. 1999: Activation of p53 by conjugation to the ubiquitin-like protein SUMO-1. EMBO Journal, 18; 6462-6471.

Greidinger, E.L., Miller, D.K., Yamin, T.T., Casciola-Rosen, L., Rosen, A. 1996: Sequential activation of three distinct ICE-like activities in Fas-ligated Jurkat cells. FEBS Letters, 390; 299-303.

Griot, C., Vandevelde, M., Richard, A., Peterhans, E., Stocker, R. 1990: Selective degeneration of oligodendrocytes mediated by reactive oxygen species . Free Radical Results Communications, 11;181-193.

Gu, W., Roeder, R.G. 1997: Activation of p53 sequence specific DNA binding by acetylation of the C-terminal domain. Cell, 90; 595-606.

Halliday, A.M., McDonald, W.I., Mushin, J. 1972 : Delayed visual evoked response in opitc neuritis. Lancet, 6; 982-985.

He, Y, Grossmann, R.I., Udupa, J.K., Fulton, J., Constantinescu, C.S., Gonzales-Scrano, F., Babb, J.S., Mannon, L.J., Kolson, D.L., Cohen, J.A. 2000: Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS. Quantitative MR assessment. Neurology, 54; 813-817.

[Seite 53↓]

He B., Xu C., Yang B., Landtblom, A.M., Fredrikson, S., Hillert, J. 1998a: Linkage and association analysis of genes encoding cytokines and myelin proteins in multiple sclerosis. Journal of Neuroimmunology, 86; 13-19.

He, B., Yang, B., Lundahl, J., Fredrikson, S., Hillert, J. 1998b: The myelin basic protein gene in multiple sclerosis: identification of discrete alleles of a 1.3 kb tetranucleotide repeat sequence. Acta Neurologica Scandinavica, 97; 46-51.

Hernan, M.A., Zhang, S.M., Lipworth, L., Olek, M.J., Ascherio, A. 2001: Multiple sclerosis and age at infection with common viruses. Epidemiology, 12; 301-306.

Hockenbery, D., Nunez, G., Milliman, C., Schreiber, R.D., Korsmeyer, S.J. 1990: Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature, 348; 334-336.

Hogancamp, W.E., Rodriguez, M., Weinshenker, B.G. 1997: The epidemiology of multiple sclerosis. Mayo Clinic Proceedings , 72; 871-878.

Hohlfeld, R . 1999: Therapeutic strategies in multiple sclerosis. I. Immunotherapy. Philosophical Transactions of the royal society: Biological Sciences, 1390; 1697-1710.

Hou J.B., Zhang Z.X. 1992: Prevalence of multiple sclerosis: a door-to-door survey in Lan Cang La Hu Zu Autonomous County, Yunnan Province of China. Neuroepidemiology, 11; 52.

Huppertz, B., Frank, H.G., Kaufmann, P. 1999: The apoptosis cascade – morphological and immunhistochemical methods for its visualisation. Anatomy and Embryology, 200; 1-18.

Juurlink, B. H. J., Thorburne, S.K., Hertz, L 1998: Peroxide-Scavenging Deficit Underlies Oligodendrocyte Susceptibility to Oxidative Stress. Glia, 22; 371-378.

[Seite 54↓]

Karaarslan, E., Altintas, A., Senol, U., Yeni, N., Dincer, A., Bayindir, C., Karaagac, N., Siva, A. 2001: Balo´s Concentric Sclerosis: Clinical and Radiologic Features of Five Cases. American Journal of Neuroradiology, 22; 1362-1367.

Kassiotis, G., Bauer, J., Akassoglou, K., Lassmann, H., Kollias, G., Probert, L. 1999: A tumor necrosis factor-induced model of human primary demyelinating dieseases developes in immunodeficient mice. European Journal of Immunology, 29; 912-917.

Kerr, J.F., Gobe, G.C., Winterford, C.M., Harmon, B.V. 1995: Anatomical methods in cell death. Methods in Cell Biology, 46;1-27.

Kira, J., Kanai, T., Nishimura, Y., Yamasaki, K., Matsushita, S., Kawano, Y., Hasuo, K., Tobimatsu, S., Kobayashi, T. 1996: Western versus Asian types of multiple sclerosis: immunogenetically and clinically distinct disorders. Annals of Neurology, 40; 569-574.

Kuhlmann, T., Lucchinetti, C., Zettl, U.K., Bitsch, A., Lassmann, H., Brück, W. 1999: Bcl-2-Expressing Oligogodendrocytes in Multiple Sclerosis Lesions . Glia, 28; 24-39.

Kuroiwa, Y., Igata, A. Itahara, K., Koshijima, S., Tsubaki, T. 1975: Nationwide survey of multiple sclerosis in Japan. Clinical analysis of 1084 cases. Neurology, 25; 845-851.

Kurtzke, J.F. 1995: MS epidemiology world wide. One view of current status. Acta Neurologica Scandinavica, Suppl. 1995; 161; 23-33.

Ladiwala, U., Li, H., Antel, J.P., Nalbantoglu, J. 1999: p53 Induction by Tumor Necrosis Factor- α and Involvement of p53 in Cell Death of Human Oligodendrocytes. Journal of Neurochemistry, 73; 605-611.

Lassmann, H.: Pathology of multiple sclerosis. In: McAlpine´s multiple sclerosis, (ed. A. Compston), 3rd edn ., London: Churchill Lvingstone, 1998 . pp. 323-358

[Seite 55↓]

Lassmann, H.: The Pathology of Inflammatory Demyelinating Lesions. In: Comparative Neuropathology of Chronic Experimental Allergic Encephalomyelitis and Multiple Sclerosis. Berlin, Heidelberg: Springer, 1983. pp. 9-95.

Lin, Y., Ma, W., Benchimol, S . 2000: Pidd, a new death-domain-containing protein, is induced by p53 and promotes apoptosis . Nature Genetics, 26; 124-127.

Liu, X., Zou, H., Slaughter, C., Wang, X . 1997: DFF, a heterodimeric protein that functions downstream of caspase-3 to trigger DNA fragmentation during apoptosis. Cell, 89; 175-184.

Lublin, F.D., Reingold, S.C. 1996: Defining the clinical course of multiple sclerosis: results of an international survey. Neurology, 46; 907-911.

Lucchinetti,C., Brück, W., Parisi, J., Scheithauer, B. Rodriguez, M., Lassmann, H. 2000: Heterogeneity of multiple sclerosis: implications for the pathogenesis of demyelination. Annals of Neurology, 47; 707-717.

Lucchinetti, C., Brück, W., Parisi, J., Scheithauer, B., Rodriguez, M., Lassmann, H. 1999 : A quantitative analysis of Oligodendrocytes in multiple sclerosis lesions. Brain, 122; 2279-2295.

Lucchinetti, C.F., Brück, W., Rodriguez, M., Lassmann, H. 1998: Multiple Sclerosis: Lessons from Neuropathology. Seminars in Neurology, 18; 337-350.

Lucchinetti, C.F., Brück, W., Rodriguez, M., Lassmann, H. 1996: Distinct Patterns of Multiple Sclerosis Pathology Indicates Heterogeneity on Pathogenesis. Brain Pathology, 6; 259-274.

Luomala, M., Elovaara, I., Ukkonen, M., Koivula, T., Lehtimäki, T. 2001 : The combination of HLA-DR1 and HLA-DR53 protects against MS. Neurology, 56; 383-385.

[Seite 56↓]

Marrosu, M.G., Murru, M.R., Costa, G., Cucca, F., Sotgiu, S., Rosati, G., Muntoni, F. 1997: Multiple Sclerosis in Sardinia is associated and in linkage disequilibrium with HLA-DR3 and –DR4 alleles. American Journal of Human Genetics, 61; 454-457.

Martin, S.J., Reutelingsperger, C.P., McGahon, A.J., Rader, J.A., van Schie, R.C., LaFace, D.M., Green, D.R. 1995: Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. Journal of Experimental Medicine, 182; 1545-1556.

Mason, J.L., Jones, J.J, Taniike, M., Morell, P., Suzuki, K., Matsushima, G.K. 2000: Mature Oligodendrocyte Apoptosis precedes IGF-1 Production and Oligodendrocyte Progenitor Accumulation and Differentiation During Demyelination/Remyelination. Journal of Neuroscience Research, 61; 251-262.

Masterman, T., Ligers, A., Olsson, T., Andersson, M., Olerup, O., Hillert, J. 2000: HLA-DR15 Is Associated with Lower Age at Onset in Multiple Sclerosis. Annals of Neurology, 48; 211-219.

McCarthy, N.J., Whyte, M.K,, Gilbert, C.S., Evan, G.I. 1997: Inhibition of Ced-3/ICE-related proteases does not prevent cell death induced by oncogenes, DNA damage, or the Bcl-2 homologue Bak. Journal of Cell Biology;136; 215-227.

McDonald, W.I., Ron, M.A. 1999 : Multiple sclerosis: the disease and its manifestations. Philosophical Transactions of the royal society: Biological Sciences, 1390; 1615-1622.

McDonald, W.I., Compston, A., Edan, G., (and 13 others) 2001: Recommended Diagnostic Criteria for Multiple Sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis . Annals of Neurology, 50; 121-127.

McDonnell, G.V., Mawhinney, H., Graham, C.A., Hawkins, S.A., Middleton, D. 1999: A study of the HLA-DR region and clinical subgroups of multiple sclerosis and ist influence on prognosis. Journal of Neurological Sciences, 165; 77-83.

[Seite 57↓]

Mews, I., Bergmann, M., Bunkowsky, S., Gullotta, F., Brück, W. ,1998: Oligodendrocyte and axon pathology in clinically silent multiple sclerosis lesions. Multiple Sclerosis , 4; 55-62.

Mignotte, B., Vayssiere, J.L. 1998: Mitochondria and apoptosis . European Journal of Biochemistry, 252; 1-15.

Müller-Ladner, U., Nishioka, K. 2000: p53 in rheumatoid arthritis: friend or foe? Arthritis Research, 2; 175-178.

Multiple Sklerose-Therapie-Konsensus-Gruppe (MSTKG) 1999: Immunmodulatorische Stufentherapie der multiplen Sklerose . Nervenarzt, 70; 371-386.

Multiple Sklerose-Therapie-Konsensus-Gruppe (MSTKG) 2001: Immunmodulatorische Stufentherapie der multiplen Sklerose. Nervenarzt, 1. Ergänzung: Dezember 2000. 72; 150-157.

Myashita, T., Reed, J.C. 1995 : Tumor supressor p53 is a direct transcriptional activator of the bax gene. Cell, 80; 293-299.

Mycko, M.P., Kwinowski, M., Tronczynska, E., Szymanska, B., Selmaj, K.W. 1998: Multiple Sclerosis: the increased frequency of the ICAM-1 exon 6 gene point mutation genetic type K469 . Annals of Neurology, 44; 539-542.

Nakajima, T., Morita, K., Ohi, N., Arai, T., Nozaki, N., Kikuchi, A., Osaka, F., Yamao, F., Oda, K. 1996: Degradation of topoisomerase II alpha during adenovirus E1A-induced apoptosis is mediated by the activation of the ubiquitin proteolysis system. Journal of Biological Chemistry, 271; 24842-24849.

Nakano, K. K., Vousden, K.H . 2001: PUMA, a novel proapoptotic gene, is induced by p53. Molecular Cell, 7; 683-694.

[Seite 58↓]

Noseworthy, J.H., O´Brien, P.C., Weinshenker, B.G., Weis, J.A., Petterson, T.M., Erickson, B.J., Windebank, A.J., Whisnant, J.P., Stolp-Smith, K.A., Harper Jr., C.M., Low, P.A., Romme, L.J., Johnson, M., An, K.N., Rodriguez, M 2000a: IV immunoglobulin does not reverse established weakness in MS. A double blind, placebo-controlled trial. Neurology, 55; 1135-1143.

Noseworthy, J.H., Lucchinetti, C., Rodriguez M., Weinshenker, B.G. 2000b: Multiple Sclerosis . New England Journal of Medicine, 343; 938-52.

Oda, E., Ohki, R., Murasawa, H., Nemoto, J., Shibue, T., Yamashita, T., Tokini, T., Taniguchi, T., Tanaka, N. 2000a: Noxa, a BH-3 only member of the Bcl-2 family and a candidate mediator of the p53-induced apoptosis . Science, 288; 1053-1058.

Oda, K., Arakawa, H., Tanaka, T., Matsuda, K., Tanikawa, C., Mori, T., Nishimori, H., Tamai, K., Tokino, T., Nakamura, Y., Taya, Y 2000b : p53AIP1, a potential mediator of p53-dependent apoptosis and its regulation by Ser-46-phosphorilated p53 . Cell, 102; 849-862.

Oger, J., Lai, H. 1994: Demyelination and ethnicity: experience at the University of British Columbia Multiple Sclerosis Clinic with special reference to HTLV-I-associated myelopathy in British Columbian natives . Annals of Neurology, 36; Suppl. 22-24.

Oksenberg, J.R., Baranzini, S.E., Barcellos, L.F., Hauser, S.L. 2001: Multiple Sclerosis: Genomic rewards. Journal of Neuroimmunology, 113; 171-184.

Olerup, O., Hillert, J. 1991 : HLA class II-assciated genetic susceptibility in multiple sclerosis: a critical evaluation. Tissue Antigens , 38; 1-15.

Olerup, O. Hillert, J., Fredrikson, S., Olsson, T., Kam-Hansen, S., Moller, E. Carlsson, B., Wallin, J. 1989: Primarily chronic progressive and relapsing/remitting multiple sclerosis: two immunogenetically distinct disease entities. Proceedings of the National Academy of Sciences, 86; 7113-7117.

[Seite 59↓]

Ormerod, I.E., Miller, D.H., McDonald, W.I., du Boulay, E.P., Rudge, P., Kendall, B.E., Moseley, I.F. et al. 1987: The role of NMR imaging in the assessment of multiple sclerosis and isolated neurological lesions: a quantitative study. Brain, 110; 1579-1616.

Ozawa, K., Suchanek, G., Breitschopf, H., Brück, W., Budka, H., Jellinger, K., Lassmann, H. 1994 : Patterns of oligodendroglia pathology in multiple sclerosis. Brain, 117; 1311-1322.

Page, W.F., Mack, T.M., Kurtzke, J.F., Murphy, F.M., Norman, J.E. Jr. 1995: Epidemiology of multiple sclerosis in US veterans. 6. Population ancestry and surname ethnicity as risk factors for multiple sclerosis. Neuroepidemiology, 14; 286-296.

Pavelko, K.D., Drescher, K.M., McGavern, D.B., David, S.C., Rodriguez, M. 2000: HLA-DQ Polymorphism Influences Progression of Demyelination and Neurologic Deficits in a Viral Model of Multiple Sclerosis. Molecular and Cellular Neuroscience, 15; 495-509.

Pender, M. P. 1998: Genetically determined failure of activation-induced apoptsis of autoreactive T cells as a cause of multiple sclerosis. Lancet, 351; 978-981.

Pette, M ., Fujita, K., Kitze, B., Whitaker, J.N., Albert, E., Kappos, L., Wekerle, H. 1990: Myelin basic protein-specific T lymphocyte lines from MS patients and healthy individuals. Neurology, 40; 1770-1776.

Poser, C.M., Paty, P.W., Scheinberg, L., McDonald, W.I., Davis, F.A., Ebers, G.C., Johnson, K.P., Sibley, W., Silberberg, D.H., Tourtellottee, W.W. 1983: New Diagnostic criteria for multiple sclerosis: guidelines for research protocols. Annals of Neurology, 13; 227-231.

Poser, C.M. 1994: The epidemiology of multiple sclerosis: a general overview. Annals of Neurology, 36 ; Suppl. 2: 180-193.

Poser, C.M. 1995 : Notes on the epidemiology of multiple sclerosis. Journal of the Formos Medical Association, 94; 300-308.

[Seite 60↓]

Poser, C.M., Brinar, V.V., 2001: Diagnostic criteria for multiple sclerosis. Clinical Neurology and Neurosurgery, 103; 1-11.

Prineas, J. W.: The Neuropathologgy of Multiple Sclerosis . In: Demyelinating Diseases. J.C. Koetsier (Hrsg). Amsterdam : Elsevier Science Publishers, 1985 . S. 213-257

Prineas, J.W., Barnard, R.O., Kwon, E.E., Sharer, L.R., Cho, E.S. 1993: Multiple sclerosis: remyelination of nascent lesions. Annals of Neurology, 33; 137-151.

Raine, C.S., Bonetti, B., Cannella, B. 1998: Multiple sclerosis: expression of molecules of the tumor necrosis factor ligand and receptor families in relationship to the demyelinated Plaque. Revue Neurologique, 154; 577-585.

Renvoize, C., Roger, R., Moulian, N., Bertoglio, J., Breard, J. 1997: Bcl-2 expression in target cells leads to functional inhibition of caspase-3 protease family in human NK and lymphokine-activated killer cell granule-mediated apoptosis. Journal of Immunology, 159;126-134.

Rivers, T.M., Sprunt, D.H., Berry, G.P. 1933: Observations on attempts to produce acute disseminated encephalomyelitis in monkeys. Journal of Experimental Medicine, 58; 39-53.

Rodriguez, M.S., Desterro, J.M., Lain, S., Midgley, C.A., Lane, D.P., Hay, R.T . 1999: SUMO-1 modification activates the transcriptional response of p53 . EMBO Journal, 18; 6455-6461.

Rothwell, P.M., Charlton, D., 1998: High incidence and prevalence of multiple sclerosis in south east Scotland: evidence of a genetic predisposition. Journal of Neurology, Neurosurgery and Psychiatry, 64; 730-735.

Runmarker, B., Martinsson, T., Wahlstrom, J., Anderson, O. 1994: HLA and prognosis in multple sclerosis. Journal of Neurology, 211; 385-390.

[Seite 61↓]

Ryan, K.M., Phillips, A.C., Vousden, K.H. 2001: Regulation and function of the p53 tumor supressor protein. Current Opinion in Cell Biology, 13; 332-337.

Sadovnick, A.D., Baird, P.A., Ward, R.H. 1988 : Multiple Sclerosis: updated risks for relatives . American Journal of Medical Genetics, 29; 533-541.

Sadovnick, A.D., Armstrong, H., Rice, G.P., Bulman, D. Hashimoto, L., Paty, D.W., Hashimoto, S.A., Warren, S,. Hader, W., Murray, T.J. et al. 1993: A population-based study of multiple scclerosis in twins: update . Annals of Neurology, 33; 281-285.

Sarkar, G., Yoon, H.S., Sommer, S.S. 1992: Screening for mutations by RNA single-strand conformation polymorphism (rSSCP): comparison with DNA-SSCP . Nucleic Acids Research, 20; 871-878.

Sawcer, S., Goodfellow, P.N., Compston, A. 1997: The genetic analysis of multiple sclerosis . TIG, 13; 234-239.

Scolding, N., Franklin, R., Stevens, S., Heldin, C.-H., Compston, A., Newcombe, J. 1998: Oligodendrocyte progenitors are present in the normal adult human CNS and in the lesions of multiple sclerosis. Brain, 121; 2221-2228.

Selmaj, K., Raine, C.S., Farooq, M., Norton, W.T., Brosnan, C.F. 1991: Cytokine Cytotoxity against Oligodendrocytes. The Journal of Immunology, 147; 1522-1529.

Shibasaki, H., McDonald, W.I., Kuroiwa, Y. 1981: Racial modification of clinical picture of multiple sclerosis: comparison between British and Japanese patients. Journal of Neurological Sciences, 49; 253-271.

Shieh, S-Y, Ahn, J., Tamai, K., Taya, Y., Prives, C. 2000: The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage–inducible sites. Genes & Development, 14; 289-300.

[Seite 62↓]

Soane, L., Rus, H., Niculescu, F., Shin, M.L. 1999: Inhibition of Oligodendrocyte Apoptosis by Sublytic C5b-9 Is Associated with Enhanced Synthesis of bcl-2 and Mediated by Inhibition of Caspase-3 Activation. The Journal of Immunology, 163; 6132-6138.

Song, Q., Lees-Miller, S.P., Zhang, N., Chan, D.W., Smith, G.C.M., Jackson, S.P., Alnemri, E.S., Litwack, G., Khanna, K.K., Lavin, M.F. 1996: DNA-dependend protein kinases catalytic subunit: a target for an ICE-like protease in apoptosis. EMBO Journal, 15; 3238-3246.

Sriram, S,. Stratton, C.W., Yao, S., Tharp, A., Ding, L., Bannan, J.D., Mitchell, W.M. 1999: Chlamydia pneumoniae infection of the central nervous system in multiple sclerosis . Annals of Neurology, 46; 6-14.

Stadelmann, C., Lassmann, H. 2000 : Detection of apoptosis in tissue sections. Cell Tissue Research, 301; 19-31.

Strasser-Fuchs, S., Fazekas, F., Deisenhammer, F., Nahler, G., Mamoli, B. 2000: The Austrian Immunoglobulin in MS (AIMS) study: final analysis. Multiple Sclerosis , 6 Suppl. 2; 9-13.

Tewari, M., Quan, L.T., O´Rourke, K., Desnoyers, S., Zeng, Z., Beidler, D.R., Poirer, G.G., Salvesen, G.S., Dixit, V.M. 1995 : Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose)polymerase. Cell , 81; 801-809.

Tienari, P.J,. Kuokkanen, S., Pastinen, T., Wikstrom,, J., Sajantila A., Sandberg-Wollheim, M., Palo, J., Peltonen, L. 1998: Golli-MBP gene in multiple sclerosis susceptibility. Journal of Neuroimmunology, 81; 158-167.

Vandenbroeck K., Opdenakker G., Goris A., Murru R., Billiau A., Marrosu M.G. 1998: Interferon-gamma gene polymorphism-associated risk for multiple sclerosis in Sardinia. Annals of Neurology, 44; 841-842.

Vousden, K.H. 2000 : p53: death star. Cell, 101; 691-694.

[Seite 63↓]

Vousden, K.H., vande Woude, G.F. 2000: The ins and outs of p53. Nature Cell Biology, 2; E178-E180.

Weinshenker, B.G., Santrach, P. Bissonet, A.S., McDonnel, S.K., Schaid, D., Moore, S.B., Rodriguez, M. 1998: Major histocompatibility complex class II alleles and the course and outcome of MS: a population-based study . Neurology, 51; 742-747.

Weinshenker, B.G. 2001: Plasma exchange for severe attacks of inflammatory demyelinating diseases of the central nervous system. Journal of Clinical Apheresis, 16; 39-42.

Wosik, K., Antel, J. Kuhlmann, T., Brück, W., Massie, B. Nalbatoglu, J. 2002: Oligodendrocyte injury in multiple sclerosis: a role for p53. Submitted.

Woods, D.B., Vousden, K.H. 2001: Regulation of p53 function. Experimental Cell Research, 264; 56-66.

Yu, J, Zhang, L, Hwang, P.M., Kinzler, K.W., Vogelstein, B . 2001: PUMA induces the rapid apoptosis of colorectal cancer cells . Molecular Cell, 7; 673-82.

Zipp, F., Otzelberger, K., Dichgans, J, Martin, R., Weller, M. 1998: Serum CD95 of relapsing remitting multiple sclerosis patients protects from CD95-mediated apoptosis. Journal of Neuroimmunology, 86; 151-154.

Michael Glas

Persönliche Angaben:

Nationalität: deutsch

Geburtsdatum: 10.09.1976

Geburtsort: Bayreuth

Ausbildung:

10/2002-09/2003: Studium der Medizin an der Charité der Humboldt-Universität zu Berlin

10/1997-09/2002: Studium der Medizin an der Freien Universität Berlin.

12/2003: Dritter Abschnitt der Ärztlichen Prüfung (Note: folgt)

09/2002 Zweiter Abschnitt der Ärztlichen Prüfung (Note: 2,0)

08/2000: Erster Abschnitt der Ärztlichen Prüfung (Note: 2)

09/1999: Ärztliche Vorprüfung (Note: 2,0)

06/1996: Abitur (Note: 1,7)

Praktika:

08/2003-09/2003: Elective Cardiothoracic und Surgical ICU, Lenox Hill Hospital, NYU School of Medicine, New York.Aufgaben: Intensivmedizi-nische Betreuung nach viszeralchirurgischen u. herzchirurgischen Eingrif-fen, Therapieverordnung und –verlauf

06/2003-08/2003: Unterassistentenstelle in der Chirurgischen Klinik des Stadtspital Waid, Zürich. Aufgaben: Erste u. zweite Assistenz bei Eingriffen d. gesamten viszeralchirugischen, traumatologischen u. peri-phergefässchirurgischen Spektrums, primäre Wundversorgung u. selbstän-diges Ausführen kleiner chirurgischer Eingriffe, Patientenuntersuchung und Aufnahme, Arztbriefe u. Therapieverlauf

02/2003-06/2003: Praktisches Jahr in der der Klinik für Kardiologie u. Pulmologie, Klinik für Gastroenterologie (Schwerpunkt: Endokriolo-gie) der Charité Berlin Campus Mitte: Patientenuntersuchung und Auf-nahme, Therapieverordnung und –verlauf, Arztbriefe, selbständige Durch-führung von Cardioversionen, Teilnahme an Herzkatheter- u. Echokardio-graphieuntersuchungen

10/2002-02/2003: Praktisches Jahr im Institut für Radiologie der Charité Berlin Campus Mitte: Aufgaben: Selbständige Durchführung (inkl. Aufklärungsgespräch) u. Befundung von radiologischen u. neurora-diologischen CT-, MRT-, Ultraschall- und Röntgenuntersuchungen

8/2001-02/2002: Studentische Hilfskraft am Institut für Neuropatholo-gie der Charité Berlin. Methoden: Zellkultur, In-Situ-Tailing, Western-Blot

09/2000-07/2001: Doktorarbeit: „Mutationsanalyse im p53 Gen bei Patienten mit Multipler Sklerose“ am Institut für Neuropathologie der Charité Berlin. Methoden: Immunhistochemie, PCR-SSCP, DNA-Sequen-zierung. Bewertet mit magna cum laude.

09/2001-10/2001: Famulatur in der Neurologischen Abteilung des Kaiser-Franz-Josef-Spitals, Wien. Aufgaben: Patientenuntersu-chung (inkl. EMG, EEG, Ultraschall) und Aufnahme, Therapieverord-nung und -verlauf

03/2001-04/2001: Famulatur in der Chirurgischen Klinik des Stadtspital Waid, Zürich. Aufgaben: Erste u. zweite Assistenz bei Eingriffen d. gesam-ten viszeralchirugischen, traumatologischen u. periphergefässchirurgischen Spektrums, primäre Wundversorgung u. selbständiges Ausführen kleiner chirurgischer Eingriffe, Patientenuntersuchung und Aufnahme, Arztbriefe u. Therapieverlauf

03/2000-04/2000: Famulatur in der Klinik für Anästhesiologie u. operati-ve Intensivmedizin der Charité Campus Virchow Klinikum. Aufgaben: Narkoseeinleitung, Beatmung, Intubation, Narkoseüberwachung

07/1996-07/1997: Zivildienst an der Chirurgischen und Medizinischen Klinik der Ludwig-Maximilians-Universität München. Aufgaben: Pflege-dienst, Patientenlagerung für Operationen

Publikationen:

Kuhlmann, T., Glas, M., zum Bruch, C., Mueller, W., Weber, A., Zipp, F., Brueck, W. Investigation of bax, bcl-2, bcl-x and p53 gene polymorphisms in multiple sclerosis. J Neuroimmunol 2002 Aug;129(1-2):154-60

Kuhlmann, T., Glas, M., zum Bruch C., Stadelmann, C., Lassmann, H., Brueck, W.: Increased p53 expression in MS lesions is not caused by p53 mutations. Submitted

Kuhlmann, T., Stadelmann, C., Glas, M., Zum Bruch, C., Brueck, W.: NO induces apoptotic cell death in OLN-93. Submitted.

Sprachen:

Englisch: 7 Jahre (fließend)

Französisch:5 Jahre (fließend)

Italienisch 1 Jahr (Grundkenntnisse)

Latein: 5 Jahre

PC-Kentnisse:

Sicherer Umgang mit MS-Office-Anwendungen

Andere Interessen:

Politik, Bildende Kunst, Literatur, Fussball